Effects of CYP3A4 inhibition and induction on the pharmacokinetics and pharmacodynamics of tolvaptan, a non-peptide AVP antagonist in healthy subjects.

What Was Tested

This randomized controlled trial looks at Tesofensine (non-peptide) and Nootropic adjuncts (non-peptide).

This paper describes the changes in tolvaptan PK and PD following inhibition or induction of CYP3A4 and explores the mechanisms behind the disparity seen between tolvaptan PK and effects on urine output.

It also discusses the concentrations at which tolvaptan produces its maximal response on urine output and the timing of the onset and offset of this response.

Who Took Part

According to the abstract, 24 subjects were involved.

By PubMed's age tags, the people studied were teenagers, young adults, adults and middle-aged adults, both men and women.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

Because people in this Tesofensine (non-peptide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the subjects and researchers unaware of who received Tesofensine (non-peptide).

The comparison arm used a placebo, so changes seen with Tesofensine (non-peptide) could be set against what happens without it.

What Was Measured

Topics PubMed links to this paper include 14-alpha Demethylase Inhibitors, Antidiuretic Hormone Receptor Antagonists, Area Under Curve, Benzazepines, Cytochrome P-450 CYP3A, Cytochrome P-450 CYP3A Inhibitors and Drug Interactions.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Tesofensine (non-peptide) and Nootropic adjuncts (non-peptide) in 24 subjects.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2012 (British journal of clinical pharmacology), a journal based in England.

More context: the Tesofensine (non-peptide) compound page and the Nootropic adjuncts (non-peptide) compound page, all human trials.